SINOFRESH HEALTHCARE INCORPORATED (OTC: SFSH) "Up 11.11% in morning trading"
SinoFresh HealthCare, Inc. is a publicly traded company based in Venice, Florida, that manufactures and distributes nasal, oral and topical antiseptic germ-killing products. SinoFresh products are marketed and distributed globally through a network of strategic wholesale and retail partners. SinoFresh Healthcare, Inc's, premier product, SinoFresh Antiseptic Homeopathic Nasal spray has in laboratory tests shown effective antiseptic capability against a variety of pathogens such as MRSA, E-Coli, H1N1 and a broad range of other viruses, molds, fungi and bacteria.
MEDICAL MARIJUANA INCORPORATED (OTC: MJNA) "Up 58.02% in morning trading"
Medical Marijuana, Inc. recognizes the vast and unequaled opportunities that exist in the rapidly expanding hemp and medical marijuana industries. The scientific recognition of cannabis has brought legalized marijuana use to the forefront of mainstream discussion thus opening the door for safe and lucrative investment opportunities.
GENTA INCORPORATED (OTCBB: GNTA) "Up 72.73% in morning trading"
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company is developing tesetaxel, a novel, orally absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel. As the leading oral taxane in clinical development, tesetaxel has been evaluated in a broad program of completed or ongoing Phase 2a/Phase 2b clinical trials. The Company has announced that gastric (stomach) cancer will be the lead indication for Phase 3 registration studies. Genasense® (oblimersen sodium) Injection is a modified DNA-based antisense drug that may enhance the effectiveness of anticancer therapy. Genta has completed enrollment in a randomized, double-blind Phase 3 study of Genasense® in patients with advanced melanoma, known as "AGENDA". Final data on survival and durable response from AGENDA, which may be pivotal for regulatory approval, are expected in the first half of 2011. Genta is exclusively marketing Ganite® (gallium nitrate injection) in the U.S., which is indicated for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed proprietary oral formulations of the active ingredient in Ganite® that are being evaluated as potential treatments for diseases associated with accelerated bone loss. Ganite® and Genasense® are available on a "named-patient" basis in countries outside the United States.
GNTA News:
March 30 - Genta Incorporated Reports Fourth Quarter and 2010 Year-End Financial Results and Updates Key Product and Corporate Developments
Genasense®: Survival data from Phase 3 melanoma trial due April 2011
Tesetaxel: Multiple clinical trial presentations expected at ASCO
Oral-Gallium Compounds: Eight candidate agents complete initial animal studies
Genta Incorporated (OTCBB: GNTA) reported results for the quarter and year ended December 31, 2010. The Company also provided an overview of recent corporate highlights and anticipated milestones.
Key Product and Corporate Developments
* Genasense® Phase 3 trial results: In April 2011, Genta expects to report final data on overall survival (OS) from AGENDA, the Company's randomized, double-blind, Phase 3 trial of dacarbazine with or without Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. Formal followup on all patients concludes in March 2011, two years from randomization of the last patient. While differences in early endpoints of overall response and progression-free survival favored the group treated with Genasense, those differences did not achieve statistical significance. The Company believes that a statistically significant increase in OS would enable submission of applications for regulatory approval of Genasense in advanced melanoma during 2011.
* Genasense® Phase 2 data in melanoma: A Phase 2 trial of Genasense plus Abraxane® and Temodar® as 1st-line treatment of patients with advanced melanoma has yielded promising results. Final response and survival data from this trial have been submitted for presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2011.
* Tesetaxel Phase 3 program: The Company is currently recruiting investigator sites for a proposed multinational, Phase 3, randomized study of tesetaxel in patients with advanced gastric (stomach) cancer. Tesetaxel has received both Fast Track and Orphan Drug designations for this indication by the U.S. Food and Drug Administration (FDA). The Company has completed the "Scientific Advice" process for this trial with the European Medicines Agency. Discussions regarding this protocol have also been held with regulatory authorities in the U.S. and Japan. The IND process has also been initiated in Korea and China.
* Tesetaxel Phase 2 Program and Special Studies: In the past 12 months, Genta has initiated a broad Phase 2 program in other priority diseases including breast, prostate, and bladder cancer, as well as melanoma. Initial data from several of these trials have been submitted for presentation at ASCO. The Company expects to present results from its weekly dose-ranging and pharmacokinetic study of tesetaxel at the ASCO meeting, and to advance this new schedule into an ongoing trial in women with advanced breast cancer. Based on promising clinical results, the company will convene an expert advisory panel to identify a potential regulatory strategy for tesetaxel in breast cancer.
* Ganite® Clinical Trials: During 2010, the Company reported initial data from a clinical and pharmacokinetic study of Ganite® (gallium nitrate injection) to treat chronic lung infections with Pseudomonas aeruginosa. Several preclinical studies have shown that gallium nitrate has potent anti-infective activity against certain drug-resistant bacteria. The Company is supplying Ganite® at no charge for an ongoing clinical study in patients with cystic fibrosis who are susceptible to resistant bacterial infections, which is being jointly conducted by the University of Washington and University of Iowa. The study is funded in part by FDA, the National Institutes of Health, and the Cystic Fibrosis Foundation. The Company continues to supply Ganite® for a clinical trial in patients with advanced non-Hodgkin's lymphoma who have relapsed from bone marrow transplantation.
* Oral Gallium Compounds: In 2010, Genta extended its internal research and development program on oral gallium-containing compounds. The program goal is to isolate novel, patentable, orally bioavailable compounds that can achieve specific target plasma concentrations that are known to be active. A number of compounds have completed initial animal testing. The Company hopes to identify a lead compound from this group and to file an Investigational New Drug (IND) exemption with FDA during 2011. Clinical work with such compounds will focus primarily on diseases associated with accelerated bone loss, with potential secondary anticancer indications.
* Intellectual Property: In the past 8 months, the Company has filed 5 patent applications on processes and intermediate compounds used in the manufacturing of tesetaxel. In 2010, two U.S. patents were issued, and the Company has filed 2 new patent applications on compositions and therapeutic uses of novel oral gallium-containing compounds.
Financial Results
For the fourth quarter of 2010, the Company reported a net loss of $(33.9) million, or net loss per basic and diluted share of $(14.46) per share, compared with a net loss of $(11.7) million or $(317.71) per basic and diluted share, for the fourth quarter of 2009. All share and per share data included in this press release have been retroactively adjusted to account for the effect of a 1-for-100 reverse stock split that became effective in August 2010 and a 1-for-50 reverse stock split that became effective in February 2011. The results for the fourth quarter of 2010 include the impact of mark-to-market accounting for certain of the Company's warrants.
For the year ended December 31, 2010, the Company reported a net loss of $(167.3) million, or $(246.04) per basic and diluted share, compared with a net loss of $(86.3) million, or $(4,200.99) per basic and diluted share, for the year ended December 31, 2009. The results for both years include the impact of mark-to-market accounting for the liabilities for the conversion features of the Company's notes, debt warrants and warrants that were issued in its financings, up until the times that the Company had sufficient shares to accommodate conversions of all of those instruments. Presently, the Company has approximately 53 million outstanding shares of common stock.
At December 31, 2010, Genta had cash and cash equivalents totaling $12.8 million, compared with $1.2 million at December 31, 2009. Net cash used in operating activities for the twelve months ended December 31, 2010 was $14.3 million, or approximately $1.2 million per month. We project that our average net monthly cash outflow will be approximately $1.5 million during 2011.
EL MANIEL INTERNATIONAL INCORPORATED (OTC: EMLL)
"Up 20.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EMLL.php
El Maniel International, Inc. intends to manufacture and distribute cigars under the PLC brand name in the United States. The company was founded in 2007 and is based in Raleigh, North Carolina. As of March 10, 2010, El Maniel International, Inc. operates as a subsidiary of Co-Max International Ltd.
EMLL News:
March 28 - El Maniel International Inc Enters Into Discussion for Gold Supply From Mali; Launches 2011 Webcast
El Maniel International Inc. (OTC: EMLL) announced that the Company has entered into discussions for the long-term supply of gold from Mali, Western Africa. "In view of the overwhelming demand received, we are currently expanding our resource base and under our trading arm, we are venturing into Mali to engage in long-term supply of the precious metal," according to Jamie Khoo, CEO of El Maniel International Inc. "Our gold trading arm in Ghana will eventually operate as our regional hub for future transactions and this enables us to sign up for more forward contracts to deliver physical gold."
Mali is also situated in Western Africa and it borders Algeria on the north, Niger on the east, Burkina Faso and the Cote d'Ivoire on the south, Guinea on the south-west, and Senegal and Mauritania on the west.
"El Maniel International remains focused in the gold business and we are rigorously capitalizing on this domain by increasing our resource base to bring value to the Company," states Jamie Khoo. "We are very pleased to launch El Maniel's 2011 Webcast via our website so as to efficiently and effectively deliver updates and developments of the Company to all our supportive shareholders and stakeholders across the globe."
El Maniel International Inc is a publicly traded company currently focused on prospecting, developing and expanding the economic potential of world class mining claims located in Ghana , West Africa and the company is committed to shareholder's value creation by ensuring constant development of current and new resources in the region.
NEURO-BIOTECH CORPORATION (OTC: MRES)
"Up 11.52% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/MRES.php
Neuro-Biotech Corp. engages in the exploration and development of mineral properties in Canada. The company primarily explores for zinc and copper ores. It holds interests in 292 mining claims located in the Matagami Mining Camp in the province of Quebec. The company was formerly known as M45 Mining Resources Inc. and changed its name to Neuro-Biotech Corp. on June 17, 2010. Neuro-Biotech is based in Montreal, Canada.
MRES News:
March 30 - MRES Announces Resumption of the Buyout Offer at $0.15 From Auric
Neuro-Biotech Corp. (OTC: MRES) announces the resumption of the buyout offer at $0.15 by AURIC Pharma Science.
Following a letter received over the weekend by AURIC, Neuro-Biotech management has decided that it was in both the Company's and shareholders best interest to proceed with the buyout offer. Therefore, the Company would like to announce the completion of its due diligence process and that it will proceed to the closing session of this transaction by Tuesday April 5, 2011. The Company will be announcing the exact time and place of the closing session on Thursday March 31, 2011.
BLUE GOLD BEVERAGES INCORPORATED (OTC: BGBV)
"Up 33.33% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BGBV.php
Blue Gold Beverages, Inc. is a leading high end producer of private label water and specialty beverages in North America. Some of our products include all natural sodas, teas, non-alcoholic wine coolers and energy drinks. Blue Gold Beverages head office situated in Montreal, Quebec, Canada, we use 3rd party bottling plants strategically located across North America depending on the geographical location of our clients. With the recent acquisition of TY Recycling, Blue Gold Beverages has entered into the polymer Recycling business, selling PET and Nylon waste. This is in-line with the company's strategy of becoming environmentally responsible by eliminating its carbon footprint, and increasing shareholder value.
About OTCPicks.com
OTCPicks.com, one of the leading penny stock Web sites, presents its daily Stocks to Watch and Midday Market Movers every weekday. In addition to all the latest penny stock news, OTCPicks also offers daily newsletters, unique commentaries and free profiles, alerts and investing tips.
The stocks presented above are available in OTCPicks.com's Free Daily Email Newsletter. For daily penny stock alerts CLICK HERE.
Disclosure: OTCPicks.com has been compensated five thousand dollars by a third party for SFSH promotional email services.
